

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Zai Lab Limited**  
**再鼎醫藥有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 9688)**

## **DEFINITIVE ADDITIONAL MATERIALS/ SUPPLEMENTAL ANNOUNCEMENT TO THE CIRCULAR FOR EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS**

We filed the attached definitive additional materials (the “**Definitive Additional Materials**”) for the extraordinary general meeting of shareholders (the “**EGM**”) of Zai Lab Limited (the “**Company**”) on March 23, 2022 (U.S. Eastern Time) with the Securities and Exchange Commission of the United States to announce that due to the public health impact of the coronavirus (COVID-19) pandemic and the recent pandemic-related restrictions in Shanghai, the format of the EGM of the Company to be held on March 28, 2022 at 8:00 a.m. (U.S. Eastern Time)/8:00 p.m. (Hong Kong Time) has been changed and will be held in a virtual meeting format only. The Definitive Additional Materials also serve as a supplemental announcement to the circular to holders of the ordinary shares of the Company pursuant to Rule 13.73 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The Definitive Additional Materials are also available for viewing on the Company’s website at <https://ir.zailaboratory.com/>. For further details of our filing, please refer to the attached Definitive Additional Materials.

By order of the Board

**Zai Lab Limited**

**Samantha Du**

*Director, Chairperson and Chief Executive Officer*

Hong Kong, March 23, 2022

*As at the date of this announcement, the board of directors of the Company comprises Dr. Samantha Du as a director, and Dr. Kai-Xian Chen, Dr. John Diekman, Ms. Nisa Leung, Mr. William Lis, Mr. Leon O. Moulder, Jr., Mr. Peter Wirth, Mr. Scott W. Morrison and Mr. Richard Gaynor as the independent directors.*

\* For identification only

---

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934  
(Amendment No.    )**

---

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

- ☐ Preliminary Proxy Statement
- ☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- ☐ Definitive Proxy Statement
- ☒ Definitive Additional Materials
- ☐ Soliciting Material under §240.14a-12

**ZAI LAB LIMITED**  
(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- ☒ No fee required.
- ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

- ☐ Fee paid previously with preliminary materials.

☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

---

---

*This document shall also serve as a circular to holders of the ordinary shares of Zai Lab Limited for purposes of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, or the HK Listing Rules.*



4560 Jinke Road  
Bldg. 1, Fourth Floor  
Pudong, Shanghai, China 201210  
(Nasdaq Trading Symbol: ZLAB; HKEx Stock Code: 9688)

**ADDITIONAL INFORMATION REGARDING EXTRAORDINARY MEETING OF STOCKHOLDERS TO BE HELD ON MONDAY,  
MARCH 28, 2022**

On March 23, 2022, Zai Lab Limited (the “Company”) issued the press release that follows, relating to a change in the format of the Company’s extraordinary general meeting of shareholders (the “EGM”) to be held on Monday, March 28, 2022 at 8:00 a.m. (U.S. Eastern Time) / 8:00 p.m. (Hong Kong Time). As described in the press release, due to the public health impact of the coronavirus (COVID-19) pandemic and the recent pandemic-related restrictions in Shanghai, the format of EGM has been changed and will be held in a virtual meeting format only.

In addition, the Notice of Change of Format following the press release supplements the Notice of Extraordinary General Meeting of Shareholders (the “Notice”) and Proxy Statement (the “Proxy Statement”) of the Company filed with the Securities and Exchange Commission (the “SEC”) and mailed or otherwise made available to the Company’s shareholders and others on February 28, 2022 in connection with the solicitation of proxies by the Company’s Board of Directors for use at the EGM.

These supplemental proxy materials are being filed with the SEC and made available to shareholders on March 23, 2022.

**THIS NOTICE SHOULD BE READ IN CONJUNCTION WITH THE NOTICE AND PROXY STATEMENT. ALL OF THE INFORMATION IN THE NOTICE AND PROXY STATEMENT CONTINUES TO APPLY EXCEPT AS AMENDED OR SUPPLEMENTED BY THIS SUPPLEMENT.**



## **Zai Lab Announces Change to Virtual Extraordinary General Meeting of Shareholders to be Held on March 28, 2022**

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass. March 23, 2022 (EDT)—Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and the recent pandemic-related restrictions in Shanghai, the format of the extraordinary general meeting of shareholders (EGM) of Zai Lab Limited has been changed and will be held in a virtual meeting format only. The purpose of the EGM is to consider and vote on a proposal relating to a proposed 1-to-10 share subdivision of the ordinary shares of Zai Lab Limited. As previously announced, the EGM will be held on March 28, 2022 at 8:00 a.m. (U.S. Eastern Time) / 8:00 p.m. (Hong Kong Time).

Shareholders of record of our ordinary shares as of the relevant record date may attend the EGM virtually by visiting our EGM website at [www.virtualshareholdermeeting.com/ZLAB2022SM](http://www.virtualshareholdermeeting.com/ZLAB2022SM). Shareholders will need the 16-digit control number included on their proxy card or on the instructions that accompanied their proxy materials. Shareholders are encouraged to log in to this website and pre-register for the EGM before the start time of the meeting. Online check-in will begin 15 minutes prior to the start of the meeting, and shareholders should allow ample time for the online check-in procedures. The proxy materials previously distributed will not be updated to reflect the change in format, but may continue to be used to vote your shares in connection with the EGM.

### **About Zai Lab**

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing, and commercializing our portfolio in order to impact human health worldwide.

For additional information about Zai Lab, please visit [www.zailaboratory.com](http://www.zailaboratory.com) or follow us at [www.twitter.com/ZaiLab\\_Global](https://twitter.com/ZaiLab_Global).

### **For more information, please contact:**

**Investor Relations:** Ron Aldridge / Lina Zhang

+1 (781) 434-8465 / +86 136 8257 6943

[ronald.aldridge@zailaboratory.com](mailto:ronald.aldridge@zailaboratory.com) / [lina.zhang@zailaboratory.com](mailto:lina.zhang@zailaboratory.com)

**Media:** Danielle Halstrom / Xiaoyu Chen

+1 (215) 280-3898 / +86 185 0015 5011

[danielle.halstrom@zailaboratory.com](mailto:danielle.halstrom@zailaboratory.com) / [xiaoyu.chen@zailaboratory.com](mailto:xiaoyu.chen@zailaboratory.com)



Source: Zai Lab Limited

**NOTICE OF CHANGE OF FORMAT  
OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF  
ZAI LAB LIMITED  
TO BE HELD ON MONDAY, MARCH 28, 2022**

Dear Shareholders,

Notice is hereby given that, due to the public health impact of the coronavirus (COVID-19) pandemic and the recent pandemic-related restrictions in Shanghai, the format of the extraordinary general meeting of shareholders (the “EGM”) of Zai Lab Limited (the “Company”) to be held on March 28, 2022 at 8:00 a.m. (U.S. Eastern Time) / 8:00 p.m. (Hong Kong Time) has been changed and will be held in a virtual meeting format only.

There is no change to the items of business to be addressed at the EGM, which are described in the proxy materials previously made available to the Company’s shareholders. As described in those proxy materials, shareholders of record of our ordinary shares as of 4:30 p.m. (Hong Kong Time) on February 18, 2022 may attend the EGM virtually by visiting our EGM website at [www.virtualshareholdermeeting.com/ZLAB2022SM](http://www.virtualshareholdermeeting.com/ZLAB2022SM). Shareholders will need the 16-digit control number included on their proxy card or on the instructions that accompanied their proxy materials. Shareholders are encouraged to log in to this website and pre-register for the EGM before the start time of the meeting. Online check-in will begin 15 minutes prior to the start of the meeting, and shareholders should allow ample time for the online check-in procedures. The proxy materials previously distributed will not be updated to reflect the change in format, but may continue to be used to vote your shares in connection with the EGM.

By Order of the Board of Directors,



Samantha (Ying) Du  
Director, Chairwoman of the Board of Directors and Chief Executive Officer  
March 23, 2022